KRas, in addition to Tp53 is a driver for early carcinogenesis and a molecular target in a mouse model of invasive gastro-esophageal adenocarcinoma
A. Anand, L. Schoemig, S. Lange, L. Tran, K. Flisikowski, R. Oellinger, R. Rad, M. Vieth, K. Steiger, T. Baumeister, J. Strangmann, H. Alguel, K. Ciecielski, K. Boettcher, H.-Y. Fang, , M. Quante
This study identifies KRAS mutation as a driver of invasive gastro-esophageal adenocarcinoma in a mouse model, showing its synergistic role with Tp53 or Rb1 loss and potential as a therapeutic target.
bioRxiv · May 7, 2024 · PreprintCancer Biology